Aarti Drugs Ltd Q2 FY26 – When APIs Meet Auditors, Chlorine Leaks, and Courtroom Drama Worth ₹230 Crore
1. At a Glance
Aarti Drugs Ltd (ADL), the ₹4,516 crore market-cap smallcap pharma daredevil, just dropped its Q2 FY26 numbers, and it’s giving us more twists than a daily soap. The company reported revenue of ₹652.9 crore and PAT of ₹45.2 crore, marking a 29.3% jump in profits YoY, even as the API market remains flatter than a paracetamol strip left in the sun.
The stock trades at ₹491/share, barely moving in the last 3 months (–0.06%), yet up 17% in 6 months. It’s valued at a P/E of 22.7x, EV/EBITDA of 15.5x, and ROE of 12.7% — not bad, but not enough to make big pharma jealous. The company’s debt stands at ₹573 crore, implying a Debt/Equity ratio of 0.39, which is the pharma equivalent of “manageable BP levels.”
But Aarti Drugs isn’t just about APIs — it’s also about legal battles (Rs.230.7 crore IGST case), environmental hiccups (HCl leak at Tarapur), and big dreams (Sayakha greenfield project going commercial). Think of it as a desi version of Breaking Bad — less chemistry class, more compliance headaches.
2. Introduction – APIs, Capex, and a Courtroom Cameo
In the labyrinthine world of Indian pharma, Aarti Drugs Ltd is that overachiever cousin — top of the class in making Active Pharmaceutical Ingredients (APIs), yet constantly under the teacher’s radar for “disciplinary issues.”
Founded in 1984 and part of the ₹1,000 million Aarti Group, the company manufactures and sells APIs, pharma intermediates, specialty chemicals, and formulations, exporting to over 100 countries. It’s like the Amazon of bulk drugs — but instead of books, it sells molecules.
In FY25, while India debated about Paracetamol’s price and China’s dumping, Aarti Drugs kept busy:
Announced ₹600 crore capex plan — partially executed.
Commissioned its Sayakha plant (Rs.220 crore) in September 2025.
Survived an HCl leak, courtesy of the MPCB’s watchful eyes.
Faced and fought a ₹230.7 crore GST demand — and won, for now, as the Bombay High Court set it aside in October 2025.
Yet amidst all this, the company posted a respectable revenue of ₹2,477 crore (TTM) and a PAT of ₹199 crore. That’s consistency with drama — a true Bollywood business story.
So, what’s cooking in Tarapur’s labs, courts, and solar farms? Let’s dive in.
3. Business Model – WTF Do They Even Do?
Aarti Drugs is in the business of making the ingredients that make your medicines work. If pharma brands are the Bollywood stars, Aarti is the camera crew behind the scenes making sure the movie actually gets shot.
a) API (81% of 9M FY25 revenue) The bread, butter, and paracetamol of Aarti’s business. It’s one of the largest global producers of molecules like Ciprofloxacin, Metronidazole, Ketoconazole, and Nimesulide. The company runs 9 manufacturing units with a 45,937 MTPA capacity. Despite pricing pressures and weaker demand, this segment still anchors the ship.
b) Formulations (11%) Through its subsidiary Pinnacle Life Science, Aarti makes 80+ formulations at its Baddi plant — 3 billion tablets and 300 million capsules per year. But FY25 wasn’t kind — this division saw a 28% YoY decline thanks to regulatory headwinds and global competition.
c) Specialty Chemicals & Intermediates (8%) A backward-integrated segment producing benzene sulfonyl chloride and other intermediates — the “raw material for the raw material.” It’s niche, chemical-heavy, and thankfully not as volatile as TikTok trends.
By therapy area, antibiotics make up 45%, followed by anti-diabetic (16%), anti-protozoal (14%), anti-inflammatory (12%), and anti-fungal (12%). If you’ve popped any of these pills, odds are you’ve indirectly supported Aarti’s revenue.
4. Financials Overview
Metric
Q2 FY26
Q2 FY25
Q1 FY26
YoY %
QoQ %
Revenue (₹ Cr)
652.9
598
591
9.1%
10.5%
EBITDA (₹ Cr)
84
67
74
25.4%
13.5%
PAT (₹ Cr)
45.2
35
54
29.3%
-16.2%
EPS (₹)
4.93
3.81
5.86
29.3%
-15.9%
Annualized EPS ≈ ₹19.7 ⇒ P/E ≈ 24.9x at CMP ₹491. That’s like paying a mid-cap premium for a mid-life crisis business.
Commentary: Margins expanded slightly despite weak API pricing — likely due to operational leverage and improved plant utilization. PAT jump is impressive, but sustainability depends on Sayakha scaling and GST ghosts staying buried.
5. Valuation Discussion – The “Fair” Value Range
Let’s get nerdy.
A. P/E Method Current EPS (TTM) = ₹21.7 Industry median P/E = 32.8 → Fair Value Range = ₹21.7 × (20–30) = ₹434 – ₹651
B. EV/EBITDA Method EV = ₹5,080 Cr, EBITDA = ₹313 Cr → EV/EBITDA = 16.2x Peer average = 18–22x → Fair Range = ₹350 – ₹520/share
C. DCF Snapshot (assuming 8% CAGR for 5 years, 11% discount rate) Fair Value = ₹470 – ₹560/share
🎯 Fair Value Range (Educational Purpose Only): ₹430 – ₹560/share (Not investment advice. We’re just connecting calculator buttons.)
